IBM Watson cuts back on drug discovery, Redox's $33M Series C and more digital health news briefs
mobihealthnews.com - 04-18
Door closes on drug discovery. IBM is tapering off sales of its Watson for Drug Discovery product in favor of other healthcare offerings using the AI technology, STAT reported this morning. The decision was made in response to weak demand and purchases from customers.